<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04248465</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-ALS-308</org_study_id>
    <secondary_id>2019-004619-30</secondary_id>
    <nct_id>NCT04248465</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Ravulizumab in ALS Participants</brief_title>
  <official_title>A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Ravulizumab in Patients With Amyotrophic Lateral Sclerosis (ALS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of ravulizumab for the
      treatment of adult participants with ALS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2020</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Ventilator Assistance-free Survival</measure>
    <time_frame>Up to Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Slow Vital Capacity</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence Of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, And TEAEs Leading To Study Drug Discontinuation</measure>
    <time_frame>Baseline through Week 156</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Muscle Strength As Assessed By Handheld Dynamometry</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline In Serum Neurofilament Light Chain</measure>
    <time_frame>Baseline, Week 50</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">354</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Ravulizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ravulizumab for the duration of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ravulizumab</intervention_name>
    <description>Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Ravulizumab</arm_group_label>
    <other_name>ALXN1210</other_name>
    <other_name>Ultomiris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria
             (possible, laboratory-supported probable, probable, or definite ALS).

          2. ALS onset ≤ 36 months from Screening.

          3. Documented meningococcal vaccination not more than 3 years prior to, or at the time
             of, initiating study treatment.

          4. Upright slow vital capacity ≥ 65% predicted at Screening.

          5. If on riluzole, participant must be on a stable dose for 30 days; if on edaravone,
             participant must be on a stable dose for 60 days (2 cycles).

          6. Body weight ≥ 40 kilograms at Screening.

          7. Contraceptive use by men or women should be consistent with local regulations
             regarding the methods of contraception for those participating in clinical studies.

        Exclusion Criteria:

          1. History of Neisseria meningitidis infection.

          2. Human immunodeficiency virus (HIV) infection (evidenced by HIV 1 or HIV 2 antibody
             titer).

          3. Dependence on invasive or non-invasive mechanical ventilation.

          4. Previously or currently treated with a complement inhibitor.

          5. Exposure to an investigational drug or device within 30 days of Screening or 5 half
             lives of the study drug, whichever is greater.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Neuromuscular Research Center and Clinic</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Las Vegas Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Neuromuscular Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nerve &amp; Muscle Center of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ravulizumab</keyword>
  <keyword>ALXN1210</keyword>
  <keyword>Ultomiris</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ravulizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

